Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Fortress Biotech, Inc. | v440882_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
| FORM 8-K |
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 27, 2016
|
FORTRESS BIOTECH, INC. |
||
|
(Exact Name of Registrant as Specified in Charter) |
| Delaware | 001-35366 | 20-5157386 |
|
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| 2 Gansevoort Street, 9th Floor, New York, New York | 10014 |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s Telephone Number, Including Area Code: (781) 652-4500
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01. | Other Events. |
On May 27, 2016, Checkpoint Therapeutics, Inc. (“Checkpoint”), a Fortress Biotech, Inc. subsidiary, issued a press release announcing that it has entered into an exclusive, worldwide license agreement with Jubilant Biosys Ltd. (“Jubilant Biosys”), a subsidiary of Jubilant Life Sciences Ltd. Pursuant to the agreement, Jubilant Biosys will out-license to Checkpoint a family of patents covering compounds that inhibit BRD4, a member of the BET (Bromodomain and Extra Terminal) domain for cancer treatment. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. Checkpoint also has entered into a sub-license agreement with TG Therapeutics, Inc. to develop and commercialize the BET inhibitor program in the field of hematological malignancies.
| Item 9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits |
| Exhibit No. | Description |
| 99.1 | Press release dated May 27, 2016. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| FORTRESS BIOTECH, INC. | ||
| Date: June 1, 2016 | /s/ Lindsay A. Rosenwald | |
| Name: | Lindsay A. Rosenwald | |
| Title: | Chairman, President and Chief Executive Officer | |